Telocyte careers

Both theoretical considerations and animal data make us reasonably confident that we can both prevent and largely reverse the cognitive decline seen in Alzheimer’s patients. We are planning FDA-sanctioned human trials to begin in mid-2017. Based on the rapid clinical responses seen in the lab, we plan to complete our phase 1 within six months of starting therapy. Currently, we are seeking a 5 million dollar series A equity investment.